Risk factors and prognosis for coronavirus disease 2019 among 131 hemodialysis patients during the Omicron variant epidemic

References

• Ling TC, Chen PL, Li NY, et al. Trajectory of humoral responses to two doses of ChAdOx1 nCoV-19 vaccination in patients receiving maintenance hemodialysis. Microbiol Spectr. 2023;11(2):1. doi: 10.1128/spectrum.03445-22.
   Web of Science ®Google Scholar
• Wing S, Thomas D, Balamchi S, et al. Effectiveness of three doses of mRNA COVID-19 vaccines in the hemodialysis population during the Omicron period. Clin J Am Soc Nephrol. 2023;18(4):491–9. doi: 10.2215/CJN.0000000000000108.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang L, Zhang K, et al. Immunocompromised states caused the prolonged duration of viral shedding in middle-aged and elderly hemodialysis patients infected with the Omicron variant of COVID-19. Ther Apher Dial. 2023. doi: 10.1111/1744-9987.13969.
   Google Scholar
• Cancarevic I, Nassar M, Daoud A, et al. Mortality rate of COVID-19 infection in end stage kidney disease patients on maintenance hemodialysis: a systematic review and meta-analysis. World J Virol. 2022;11(5):352–361. doi: 10.5501/wjv.v11.i5.352.
   PubMedGoogle Scholar
• Willan J, Agarwal G, Bienz N. Mortality and burden of post-COVID-19 syndrome have reduced with time across SARS-CoV-2 variants in haematology patients. Br J Haematol. 2023;201(4):640–644. doi: 10.1111/bjh.18700.
   PubMed Web of Science ®Google Scholar
• Ciuffreda L, Lorenzo-Salazar JM, Garcia M, et al. Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain). Emerg Microbes Infect. 2023;12(1):2202281. doi: 10.1080/22221751.2023.2202281.
   PubMed Web of Science ®Google Scholar
• Neumann-Podczaska A, Al-Saad SR, Karbowski LM, et al. COVID 19–clinical picture in the elderly population: a qualitative systematic review. Aging Dis. 2020;11(4):988–1008. doi: 10.14336/AD.2020.0620.
   PubMed Web of Science ®Google Scholar
• Banshodani M, Kawanishi H, Hirai T, et al. The predictive markers of severity and mortality in hospitalized hemodialysis patients with COVID-19 during Omicron epidemic. Ther Apher Dial. 2023. doi: 10.1111/1744-9987.13970.
   Google Scholar
• Bao WJ, Fu SK, Zhang H, et al. Clinical characteristics and short-term mortality of 102 hospitalized hemodialysis patients infected with SARS-CoV-2 Omicron BA.2.2.1 variant in Shanghai, China. New Microbes New Infect. 2022;49:101058. doi: 10.1016/j.nmni.2022.101058.
   PubMed Web of Science ®Google Scholar
• Nori W, Ghani Zghair MA. Omicron targets upper airways in pediatrics, elderly and unvaccinated population. World J Clin Cases. 2022;10(32):12062–12065. doi: 10.12998/wjcc.v10.i32.12062.
   PubMed Web of Science ®Google Scholar
• Banovic S, Sinanovic O, Jankovic S, et al. Communication of the elderly during the COVID-19 pandemic. Acta Inform Med. 2022;30(4):324–328. doi: 10.5455/aim.2022.30.324-328.
   PubMedGoogle Scholar
• Falcone M, Tiseo G. Skin and soft tissue infections in the elderly. Curr Opin Infect Dis. 2023;36(2):102–108. doi: 10.1097/QCO.0000000000000907.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang Y, Hu C, et al. Effectiveness of a booster dose of COVID-19 vaccines during an outbreak of SARS-CoV-2 Omicron BA.2.2 in China: a case-control study. Hum Vaccin Immunother. 2023;19(1):2194189. doi: 10.1080/21645515.2023.2194189.
   PubMed Web of Science ®Google Scholar
• Kim JS, Lee JY, Yang JW, et al. Immunopathogenesis and treatment of cytokine storm in COVID-19. Theranostics. 2021;11(1):316–329. doi: 10.7150/thno.49713.
   PubMed Web of Science ®Google Scholar
• Kitabayashi K, Yamamoto S, Narita I. Association of the nutritional risk index for Japanese hemodialysis with mortality and dietary nutritional intake in patients undergoing hemodialysis during long-term hospitalization. Clin Exp Nephrol. 2022;26(12):1200–1207. doi: 10.1007/s10157-022-02259-0.
   PubMed Web of Science ®Google Scholar
• Syed-Ahmed M, Narayanan M. Immune dysfunction and risk of infection in chronic kidney disease. Adv Chronic Kidney Dis. 2019;26(1):8–15. doi: 10.1053/j.ackd.2019.01.004.
   PubMed Web of Science ®Google Scholar
• Gheorghe G, Ilie M, Bungau S, et al. Is there a relationship between COVID-19 and hyponatremia? Medicina. 2021;57(1):55. doi: 10.3390/medicina57010055.
   PubMedGoogle Scholar
• Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848. doi: 10.1007/s00134-020-05991-x.
   PubMed Web of Science ®Google Scholar
• Wang C, Fei D, Li X, et al. IL-6 may be a good biomarker for earlier detection of COVID-19 progression. Intensive Care Med. 2020;46(7):1475–1476. doi: 10.1007/s00134-020-06065-8.
   PubMed Web of Science ®Google Scholar
• Beppu H, Fukuda T, Otsubo N, et al. Serum chemokine CC-motif ligand 17 is a predictive marker of severe COVID-19 in haemodialysis patients: a retrospective observational study. Nephrology. 2023;28(4):240–248. doi: 10.1111/nep.14151.
   PubMed Web of Science ®Google Scholar
• Pai MF, Tung KT, Hsu SP, et al. Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients. Ren Fail. 2023;45(1):2172432. doi: 10.1080/0886022X.2023.2172432.
   PubMed Web of Science ®Google Scholar
• Abdulaziz HMM, Saleh MA, Elrggal ME, et al. Egyptian hemodialysis patients’ willingness to receive the COVID-19 vaccine booster dose: a multicenter survey. J Nephrol. 2023;1–12. doi: 10.1007/s40620-023-01586-z.
   Google Scholar
• Kale A, Shelke V, Dagar N, et al. How to use COVID-19 antiviral drugs in patients with chronic kidney disease. Front Pharmacol. 2023;14:1053814. doi: 10.3389/fphar.2023.1053814.
   PubMed Web of Science ®Google Scholar
• Anderson AS, Caubel P, Rusnak JM, et al. Nirmatrelvir–ritonavir and viral load rebound in COVID-19. N Engl J Med. 2022;387(11):1047–1049. doi: 10.1056/NEJMc2205944.
   PubMed Web of Science ®Google Scholar
• Sun Y, Jin L, Dian Y, et al. Oral azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study. EClinicalMedicine. 2023;59:101981. doi: 10.1016/j.eclinm.2023.101981.
   PubMedGoogle Scholar
• Lingscheid T, Kinzig M, Kruger A, et al. Pharmacokinetics of nirmatrelvir and ritonavir in COVID-19 patients with end-stage renal disease on intermittent hemodialysis. Antimicrob Agents Chemother. 2022;66(11):e0122922. doi: 10.1128/aac.01229-22.
   PubMed Web of Science ®Google Scholar